碳青霉烯类耐药铜绿假单胞菌耐药机制与治疗现状

doi:10.12372/jcp.2023.23e0487

Abstract

Abstract:

Pseudomonas aeruginosa is a common opportunistic pathogen of nosocomial infection, which is widely distributed in the hospital environment and can survive for a long time. Carbapenems antibiotics play an important role in the treatment of serious infections caused by Pseudomonas aeruginosa. However, the outbreak of carbapenems resistant Pseudomonas aeruginosa is particularly prominent in recent years, which has made clinical treatment facing great challenges. This article introduces the main resistance mechanism of Pseudomonas aeruginosa to carbapenems antibiotics and summarizes the application of various clinical treatment schemes, and provides a reference clinical rational use of antibiotics and treatment of carbapenems resistant Pseudomonas aeruginosa infection

Key words: Pseudomonas aeruginosa, carbapenem antibiotics, resistance mechanism, treatment

YU Hui. Resistance mechanism and treatment of carbapenem resistant Pseudomonas aeruginosa[J].Journal of Clinical Pediatrics, 2023, 41(8): 561-565.

References 31

[1]	Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3): 318-327. doi: S1473-3099(17)30753-3 pmid: 29276051
[2]	Fu P, Xu H, Jing C, et al. Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED program in China, 2016 to 2020[J]. Microbiol Spectr, 2021, 9(3): e0028321.
[3]	Logan LK, Gandra S, Mandal S, et al. Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United States, 1999-2012[J]. J Pediatr Infect Dis Soc, 2017, 6(4): 352-359.
[4]	Seifert H, von Linstow Ml, Janssen H, et al. Antimicrobial susceptibility among Gram-negative isolates in pediatric patients in Europe from 2013-2018 compared to 2004-2012: results from the ATLAS surveillance study[J]. Int J Antimicrob Agents, 2021, 58(5): 106441. doi: 10.1016/j.ijantimicag.2021.106441
[5]	Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance[J]. Nat Rev Microbiol, 2015, 13(1): 42-51. doi: 10.1038/nrmicro3380 pmid: 25435309
[6]	Hancock RE, Brinkman FS. Function of Pseudomonas porins in uptake and efflux[J]. Annu Rev Microbiol, 2002, 56: 17-38. pmid: 12142471
[7]	Feng W, Huang Q, Wang Y, et al. Changes in the resistance and epidemiological characteristics of Pseudomonas aeruginosa during a ten-year period[J]. J Microbiol Immunol Infect, 2021, 54(2): 261-266. doi: 10.1016/j.jmii.2019.08.017
[8]	Daury L, Orange F, Taveau JC, et al. Tripartite assembly of RND multidrug efflux pumps[J]. Nat Commun, 2016, 7: 10731. doi: 10.1038/ncomms10731 pmid: 26867482
[9]	Dreier J, Ruggerone P. Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa[J]. Front Microbiol, 2015, 6: 660. doi: 10.3389/fmicb.2015.00660 pmid: 26217310
[10]	Hassuna NA, Darwish MK, Sayed M, et al. Molecular epidemiology and mechanisms of high-level resistance to meropenem and imipenem in Pseudomonas aeruginosa[J]. Infect Drug Resist, 2020, 13: 285-293. doi: 10.2147/IDR.S233808 pmid: 32099420
[11]	Bonnin RA, Bogaerts P, Girlich D, et al. Molecular characterization of OXA-198 carbapenemase-producing Pseudomonas aeruginosa clinical isolates[J]. Antimicrob Agents Chemother, 2018, 62(6): e02496-17.
[12]	Reyes J, Komarow L, Chen L, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseu-domonas aeruginosa and associated carbapenemases (POP): a prospective cohort study[J]. Lancet Microbe, 2023, 4(3): e159-e170.
[13]	Schauer J, Gatermann SG, Hoffmann D, et al. GPC-1, a novel class A carbapenemase detected in a clinical Pseudomonas aeruginosa isolate[J]. J Antimicrob Chemother, 2020, 75(4): 911-916. doi: 10.1093/jac/dkz536
[14]	Yin S, Chen P, You B, et al. Molecular typing and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a Chinese burn center from 2011 to 2016[J]. Front Microbiol, 2018, 9: 1135. doi: 10.3389/fmicb.2018.01135
[15]	Breidenstein EB, de la Fuente- Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance[J]. Trends Microbiol, 2011, 19(8): 419-426. doi: 10.1016/j.tim.2011.04.005 pmid: 21664819
[16]	Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution[J]. Drug Resist Updat, 2019, 44: 100640. doi: 10.1016/j.drup.2019.07.002
[17]	Botelho J, Grosso F, Peixe L. Characterization of the pJB12 plasmid from Pseudomonas aeruginosa reveals Tn 6352, a novel putative transposon associated with mobilization of the bla_VIM-2-harboring In58 integron[J]. Antimicrob Agents Chemother, 2017, 61(5): e02532-16.
[18]	van der Zee A, Kraak WB, Burggraaf A, et al. Spread of carbapenem resistance by transposition and conjugation among Pseudomonas aeruginosa[J]. Front Microbiol, 2018, 9: 2057. doi: 10.3389/fmicb.2018.02057
[19]	Xiong J, Alexander DC, Ma JH, et al. Complete sequence of pOZ176, a 500-kilobase IncP-2 plasmid encoding IMP-9-mediated carbapenem resistance, from outbreak isolate Pseudomonas aeruginosa 96[J]. Antimicrob Agents Chemother, 2013, 57(8): 3775-3782. doi: 10.1128/AAC.00423-13
[20]	López-Causapé C, Cabot G, Del Barrio-Tofiño E, et al. The versatile mutational resistome of Pseudomonas aeruginosa[J]. Front Microbiol, 2018, 9: 685. doi: 10.3389/fmicb.2018.00685 pmid: 29681898
[21]	Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms[J]. Int J Med Microbiol, 2002, 292(2): 107-113. doi: 10.1078/1438-4221-00196 pmid: 12195733
[22]	Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies[J]. Biotechnol Adv, 2019, 37(1): 177-192. doi: 10.1016/j.biotechadv.2018.11.013
[23]	Rasamiravaka T, Labtani Q, Duez P, et al. The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms[J]. Biomed Res Int, 2015: 759348.
[24]	Chambonnier G, Roux L, Redelberger D, et al. The hybrid histidine kinase lads forms a multicomponent signal transduction system with the GacS/GacA two-component system in Pseudomonas aeruginosa[J]. PLoS Genet, 2016, 12(5): e1006032.
[25]	Bordi C, Lamy MC, Ventre I, et al. Regulatory RNAs and the HptB/RetS signalling pathways fine-tune Pseudomonas aeruginosa pathogenesis[J]. Mol Microbiol, 2010, 76(6): 1427-1443. doi: 10.1111/j.1365-2958.2010.07146.x
[26]	Valentini M, Filloux A. Biofilms and cyclic di-GMP (c-di-GMP) signaling: lessons from Pseudomonas aeruginosa and other bacteria[J]. J Biol Chem, 2016, 291(24): 12547-12555. doi: 10.1074/jbc.R115.711507 pmid: 27129226
[27]	Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)[J]. Clin Infect Dis, 2022, 75(2): 187-212. doi: 10.1093/cid/ciac268
[28]	中华医学会呼吸病学分会感染学组. 中国铜绿假单胞菌下呼吸道感染诊治专家共识(2022年版)[J]. 中华结核和呼吸杂志, 2022, 45(8): 739-752.
[29]	Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)[J]. Clin Microbiol Infect, 2022, 28(4): 521-547. doi: 10.1016/j.cmi.2021.11.025
[30]	Davido B, Fellous L, Lawrence C, et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2017, 61(9): e01008-17.
[31]	王明贵. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制: 中国专家共识[J]. 中国感染与化疗杂志, 2017, 17(1): 82-93.

Resistance mechanism and treatment of carbapenem resistant Pseudomonas aeruginosa

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LUO Zhiqiang, CHEN Li, LU Xinguo, LIAO Jianxiang, LUO Xufeng. The treatment of the first case of presymptomatic spinal muscular atropy in the Chinese Mainland: a case report with 43 months follow-up [J]. Journal of Clinical Pediatrics, 2025, 43(1): 40-44.
[2]	ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55.
[3]	HUANG Shiyu, LUO Lijuan, WANG Jing, CHEN Xia, CAO Qing. Early diagnosis, treatment and follow-up of 6 children with autoinflammatory diseases caused by NLRP3 gene variation [J]. Journal of Clinical Pediatrics, 2024, 42(7): 643-647.
[4]	KANG Li, HUANG Jiaoling. The impact of infectious disease outbreaks on the pediatric healthcare system and countermeasures [J]. Journal of Clinical Pediatrics, 2024, 42(6): 475-479.
[5]	MA Tao, LU Jie, XU Hui, ZHAO Shunying, LI Huimin. Clinical characteristics of extrapulmonary tuberculosis in 473 children [J]. Journal of Clinical Pediatrics, 2024, 42(6): 491-496.
[6]	HUANG Lisu, LIN Luona, ZHANG Xianli. From practice to consensus, from consensus to practice: interpretation of Chinese expert consensus on the diagnosis and treatment of respiratory syncytial virus infections in children (2023 edition) [J]. Journal of Clinical Pediatrics, 2024, 42(6): 553-557.
[7]	LI Juan, DAI Jihong. Current status of diagnosis and treatment of protracted bacterial bronchitis in children [J]. Journal of Clinical Pediatrics, 2024, 42(4): 373-378.
[8]	GU Yutong, YANG Fen, YE Jianmin, HUA Li, LI Jing, DING Guodong. Macrolide resistance in hospitalized children with Mycoplasma pneumoniae pneumonia and its clinical diagnosis and treatment [J]. Journal of Clinical Pediatrics, 2024, 42(3): 182-186.
[9]	WANG Jian, LI Niu. New trends in the diagnosis and treatment of rare diseases in the digital medical era [J]. Journal of Clinical Pediatrics, 2024, 42(2): 96-101.
[10]	ZENG Xiangli, ZHENG Liangrong, DAI Yongqiang, YIN Gendi, HUANG Qiling, MOU Yikun, QIN Feng, ZHANG Shuqi, LI Lingwei, LI Zhicheng. Causes, clinical features, and prognosis of dizziness and vertigo in children: an 18-year retrospective analysis at a single center [J]. Journal of Clinical Pediatrics, 2024, 42(12): 1010-1014.
[11]	FENG Shuyue, ZHANG Heng, SUN Mengjiao, FANG Yongjun. Clinical efficacy analysis of AVDC/ICE regimen in the treatment of 10 pediatric extracranial malignant rhabdoid tumors [J]. Journal of Clinical Pediatrics, 2024, 42(12): 1032-1038.
[12]	JIANG Tao, LI Wenyan. Discussion on diagnosis and treatment of common diseases of vertigo in children [J]. Journal of Clinical Pediatrics, 2024, 42(12): 996-1000.
[13]	HUANG Shihao, YUAN Xiaojun. Analysis on clinical characteristics and treatment for Kasabach-Merritt phenomenon in 36 children with hemangioma [J]. Journal of Clinical Pediatrics, 2024, 42(11): 917-921.
[14]	PENG Qianqian, YANG Huandan, YUAN Tingting, QIU Shan, LI Yan, ZHOU Suqin, LU Qian. Efficacy of Belimumab combined with traditional regimen in the treatment of active lupus nephritis in children [J]. Journal of Clinical Pediatrics, 2024, 42(11): 975-982.
[15]	JIN Tong, LIU Chang, ZHAO Xue. Clinical manifestations and progress in diagnosis and treatment of digestive system involvement in children with juvenile systemic lupus erythematosus [J]. Journal of Clinical Pediatrics, 2024, 42(10): 895-901.